NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
Clinical Trials
10 trialsNCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04253262 2025-05-04
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Phase 1/2 Active not recruiting
NCT04209595 2025-03-17
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT03337087 2024-05-17
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT01482715 2023-06-09
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
Phase 1/2 Completed
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT03462212 2021-08-27
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Unknown
NCT03572478 2021-03-09
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Phase 1/2 Terminated